Fluoroquinolones and Dysglycemia

Tailor SAN Simor AE Cornish W Analysis of spontaneous reports of hypoglycemia and hyperglycemia associated with marketed systemic fluoroquinolones made to the Canadian Adverse Drug Reaction Monitoring Program. Can J Hosp Pharm 2004;57(1):12–17.

Canadian Pharmacists Association. e-CPS [database on the Internet; cited May 15, 2007]. Ottawa: Canadian Pharmacists Association; 2007.

Owens RC Jr Ambrose PG . Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(Suppl 2):S144–57.

Glucose abnormalities and fluoroquinolones. Pharmacist's Letter/Prescriber's Letter 2006;22(1):220109.

Catero M . Dysglycemia and fluoroquinolones: are you putting patients at risk? J Fam Pract 2007;56(2):101–7.

Tomita T Onishi M Sato E Gatifloxacin induces augmented insulin release and intracellular insulin depletion of pancreatic islet cells. Biol Pharm Bull 2007;30(4):644–7.

Yamada C Nagashima K Takahashi A Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol 2006;553(1–3):67–72.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27 (suppl 2).

Hopkins M . Blood sugar highs & lows. Helping adults with diabetes manage acute hypo- and hyperglycemia. Diabetes Update 2006:S12–14, 16, 18, 19. [Special supplement to the April 2006 issue of Pharmacy Practice.] Available: www.pharmacygateway.ca/pdfs/2006/04/04-DIA-Glucose-06-web.pdf (accessed June 26, 2007).

American Diabetes Association. What is hyperosmolar hyperglycemic nonketotic syndrome (HHNS)? Available: www.diabetes.org/type-2-diabetes/treatment-conditions/hhns.jsp (accessed June 25, 2007).

Park-Wyllie LY Juurlink DN Kopp A Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354(13):1352–61.

Graumlich JF Habis S Avelino RR Hypoglycemia in inpatients after gati floxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005;25(10):1296–302.

Mohr JF McKinnon PS Peymann PJ A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25(10):1303–9.

American Society of Health-System Pharmacists. AHFS Drug Information (2007). In: STAT!Ref Online Electronic Medical Library [database on the Internet; cited May 15, 2007]. Bethesda: American Society of Health-System Pharmacists; 2007.

Hunt M . Levofloxacin: dysglycemia and liver disorders. Canadian Adverse Reaction Newsletter 2007;17(1):1–2. Available: www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/carn-bcei_v17n1_e.pdf (accessed April 10, 2007).

Owens RC Jr . Fluoroquinolone-associated dysglycemias: a tale of two toxicities. Pharmacotherapy 2005;25(10):1291–5.

Health Canada. Health Canada Endorsed Important Safety Information on TEQUIN (gatifloxacin). May 12, 2006. Available: www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2006/tequin_2_hpc-cps_e.html (accessed April 4, 2007).